Datamonitor Healthcare interviewed two infectious disease experts, one based in the US and one in France, to gauge their views on the seasonal influenza vaccines market, its outlook over the next five years and any key events that are likely to take place, including the impact of novel quadrivalent inactivated influenza vaccines and other incremental advances. The vaccines discussed are Fluad, FluBlok, Flucelvax, FluMist Quadrivalent (AZN), Fluzone High Dose (SNY) and Intanza (SNY). The two interviews were combined into a single report.

As a special offer, we are pleased to make these two KOL interviews available free of charge to Biomedtracker clients.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.